Literature DB >> 11567759

Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.

W M Li1, M B Bally, M P Schutze-Redelmeier.   

Abstract

Immunostimulatory CpG oligodeoxynucleotides (ODN) have been tested as immunoadjuvants for various vaccines including T-cell independent (TI) antigens. Findings from previous reports suggest that close physical association of CpG ODN to the antigen could enhance its adjuvant effect. As an alternative to chemical conjugation of CpG ODN to the antigen, the current study is aimed at determining the benefit of using liposomes as a carrier for CpG ODN to improve the immune response to biotinylated liposomes (Bx-liposomes), a model of a TI antigen. Liposomes with suboptimal concentration of hapten (1% biotin) were not immunogenic. However, when CpG ODN encapsulated in Bx-liposomes were used to immunize mice, a hapten-specific response was obtained as indicated by antibody-mediated elimination of re-administered Bx-liposomes. CpG ODN co-administered with empty Bx-liposomes could not achieve the same effect, indicating the requirement for encapsulation of the adjuvant. Using both intravenous (i.v.) and subcutaneous (s.c.) immunization methods, it was found that IgM levels, but not IgG levels were elevated. Immunization in nude mice confirmed that the immune response obtained was TI. The use of non-CpG ODN and an ODN with alternatively flanked CpG motifs showed no adjuvant effect. Incorporation of poly(ethylene)glycol (PEG)-modified lipid in liposomes enhanced the immune response even further. In conclusion, our data shows that liposomes are a useful delivery vehicle for CpG ODN as an immune adjuvant for TI antigens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567759     DOI: 10.1016/s0264-410x(01)00277-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.

Authors:  Stacey L Demento; Alyssa L Siefert; Arunima Bandyopadhyay; Fiona A Sharp; Tarek M Fahmy
Journal:  Trends Biotechnol       Date:  2011-04-02       Impact factor: 19.536

2.  TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis.

Authors:  Stacey L Demento; Nathalie Bonafé; Weiguo Cui; Susan M Kaech; Michael J Caplan; Erol Fikrig; Michel Ledizet; Tarek M Fahmy
Journal:  J Immunol       Date:  2010-07-26       Impact factor: 5.422

3.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Antitumor activity of G3139 lipid nanoparticles (LNPs).

Authors:  Xiaogang Pan; Li Chen; Shujun Liu; Xiaojuan Yang; Jian-Xin Gao; Robert J Lee
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

Review 5.  Designer lipids for drug delivery: from heads to tails.

Authors:  Aditya G Kohli; Paul H Kierstead; Vincent J Venditto; Colin L Walsh; Francis C Szoka
Journal:  J Control Release       Date:  2014-05-06       Impact factor: 9.776

6.  Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.

Authors:  Xulang Zhang; Chee Guan Koh; Bo Yu; Shujun Liu; Longzhu Piao; Guido Marcucci; Robert J Lee; L James Lee
Journal:  Pharm Res       Date:  2009-03-17       Impact factor: 4.200

7.  Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.

Authors:  Qing Ma; Dapeng Zhou; Elizabeth S DeLyria; Xiaoxia Wen; Wei Lu; Prakash Thapa; Chengwen Liu; Dan Li; Roland L Bassett; Willem W Overwijk; Patrick Hwu; Chun Li
Journal:  J Immunother       Date:  2017-01       Impact factor: 4.456

Review 8.  Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies.

Authors:  Helena Freire Haddad; Jacqueline A Burke; Evan A Scott; Guillermo A Ameer
Journal:  Regen Eng Transl Med       Date:  2021-03-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.